Forte Biosciences FB-401 Phase 2 atopic dermatitis trial misses primary endpoint EASI-50

Forte Biosciences, Inc.

Primary endpoint EASI-50: 58% active vs 60% placebo (p=0.7567), not statistically significant.
Secondary endpoint EASI-90: 27.6% active vs 20.5% placebo (p=0.3075); IGA success: 38.2% vs 29.5% (p=0.2599).
Company will not continue development of FB-401; plans to provide future update on company direction.
Cash and cash equivalents of $50.8 million as of June 30, 2021.
Previously scheduled September 7 conference call canceled.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.